Evidence map›Paper›PMID 41032751›Full record

ArticleBlood2026

Fetal context conveys heritable protection against MLL-rearranged AML that depends on MLL3.

Jonny Mendoza-Castrejon, Wei Yang, Elisabeth Denby, Helen C Wang, Emily B Casey, Rohini Muthukumar, Riddhi M Patel, Jihye Yoon, Yanan Li, J Michael White and 3 more

Abstract read
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jonny Mendoza-CastrejonDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-9558-152X
Wei YangDepartment of Genetics, Washington University School of Medicine, St. Louis, MO.
Elisabeth DenbyDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.
Helen C WangDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-8887-1799
Emily B CaseyDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.
Rohini MuthukumarDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-8885-6935
Riddhi M PatelDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0169-1224
Jihye YoonDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-5334-0293
Yanan LiDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.
J Michael WhiteDepartment of Pathology and Immunobiology, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0001-5110-6567
Ran ChenDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-8415-7229
Luis F Z BatistaDivision of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Jeffrey A MageeDivision of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.ORCID 0000-0002-0766-4200

Funding

The role of Kmt2c/MLL3 in hematopoietic stem cell self-renewal, commitment and exhaustionR01HL152180 · NHLBI · WASHINGTON UNIVERSITY · PI Jeffrey Alan Magee · 2020 to 2026
$3.0M
Cross-species development and credentialing of pediatric AML modelsR01CA285272 · NCI · WASHINGTON UNIVERSITY · PI Jeffery M Klco, Jeffrey Alan Magee · 2024 to 2026
$2.0M
The Role of SKIDA1 in Acute Myeloid Leukemia Initiation and MaintenanceF31CA268923 · NCI · WASHINGTON UNIVERSITY · PI MENDOZA-CASTREJON, JONNY · 2023 to 2024
$69k
NCI NIH HHS F31 CA268923NCI NIH HHS R01 CA285272NHLBI NIH HHS R01 HL152180
6 · The paper itself

Abstract

abstractMLL rearrangements (MLLrs) are the most common cause of congenital and infant leukemias. MLLrs arise prior to birth and can transform fetal/neonatal progenitors with the help of only a few additional cooperating mutations. Despite the low threshold for transformation, infant leukemias are rare, and congenital leukemias, which arise before birth, are even less common. These observations raise the question of whether mechanisms exist to suppress leukemic transformation during fetal life, thereby protecting the developing fetus from malignancy during a period of rapid hematopoietic progenitor expansion. To test this possibility, we used a mouse model of temporally controlled MLL::ENL expression to show that fetal MLL::ENL exposure establishes a heritable, leukemia-resistant state within hematopoietic progenitors that persists after birth. When we induced MLL::ENL expression prior to birth and transplanted hematopoietic stem and progenitor cells, very few recipient mice developed acute myeloid leukemia (AML) despite robust engraftment. When we induced MLL::ENL expression shortly after birth, all recipient mice developed a highly penetrant AML. Fetal MLL::ENL expression imposed a negative selective pressure on hematopoietic progenitors before birth followed by loss of self-renewal gene expression and enhanced myeloid differentiation after birth that precluded transformation. These changes did not occur when MLL::ENL expression initiated shortly after birth. The fetal barrier to transformation was enforced by the histone methyltransferase MLL3, and it could be overcome by cooperating mutations, such as NrasG12D. Heritable fetal protection against leukemic transformation may contribute to the low incidence of congenital and infant leukemias in humans.

Indexed as

DNA-Binding ProteinsGene RearrangementHistone-Lysine N-MethyltransferaseLeukemia, Myeloid, AcuteMyeloid-Lymphoid Leukemia ProteinAnimalsFemaleFetusGene Expression Regulation, LeukemicHematopoietic Stem CellsHumansMiceMice, TransgenicNuclear ProteinsOncogene Proteins, FusionDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseKmt2a protein, mouseMllt3 protein, mouseMyeloid-Lymphoid Leukemia ProteinNuclear ProteinsOncogene Proteins, Fusion

Identifiers

PMID41032751
PMCPMC12758594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.